Results 221 to 230 of about 2,787,448 (332)

Targeted Therapies in Myelofibrosis: Present Landscape, Ongoing Studies, and Future Perspectives

open access: yesAmerican Journal of Hematology, Volume 100, Issue S4, Page 30-50, June 2025.
ABSTRACT Myelofibrosis (MF) is a myeloproliferative neoplasm that is accompanied by driver JAK2, CALR, or MPL mutations in more than 90% of cases, leading to constitutive activation of the JAK–STAT pathway. MF is a multifaceted disease characterized by trilineage myeloid proliferation with prominent megakaryocyte atypia and bone marrow fibrosis, as ...
Giuseppe G. Loscocco, Paola Guglielmelli
wiley   +1 more source

Allogeneic Stem Cell Transplant for Myelofibrosis and Myelodysplastic Syndromes: A Contemporary Review

open access: yesAmerican Journal of Hematology, Volume 100, Issue S4, Page 16-29, June 2025.
ABSTRACT Allogeneic hematopoietic stem‐cell transplantation (HCT) remains the only potentially curative therapy for patients with myelodysplastic neoplasms (MDS) and myelofibrosis (MF) and is the standard care for eligible patients with higher‐risk disease. Despite significant advancements, both diseases pose unique challenges due to their clinical and
Nico Gagelmann, Nicolaus Kröger
wiley   +1 more source

BCR::ABL1‐Positive Acute Myeloid Leukemia

open access: yes
American Journal of Hematology, EarlyView.
Alban Canali   +3 more
wiley   +1 more source

Cost‐Effectiveness of Ferritin Screening Thresholds for Iron Deficiency in Reproductive‐Age Women

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Iron deficiency (ID) is a top five leading cause of disability‐adjusted life‐years in women of reproductive age around the world. Despite its enormous health burden, no screening guidelines exist for the detection and treatment of ID in women of reproductive age.
Daniel Wang   +7 more
wiley   +1 more source

Five‐Year Real‐World Safety of Inotuzumab Ozogamicin Before Hematopoietic Stem Cell Transplantation in B‐Cell Precursor Acute Lymphoblastic Leukemia

open access: yes
American Journal of Hematology, Volume 100, Issue 5, Page 909-912, May 2025.
Marcos de Lima   +14 more
wiley   +1 more source

A Phase II Trial of Geriatric Assessment‐Guided Selection of Treatment Intensity in Older Adults With AML

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT How to select the appropriate intensity of chemotherapy in older adults with acute myeloid leukemia (AML) remains an unanswered question. In a phase II trial of older adults ≥ 60 years with AML (n = 73), we used geriatric assessment (measures of comorbidity burden, physical and cognitive function) to determine fitness for intensive ...
Vijaya R. Bhatt   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy